IM Cannabis (NASDAQ:IMCC – Get Free Report) and Alpha Cognition (NASDAQ:ACOG – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.
Profitability
This table compares IM Cannabis and Alpha Cognition’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IM Cannabis | -39.62% | -585.96% | -58.32% |
| Alpha Cognition | -153.61% | -54.60% | -43.47% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for IM Cannabis and Alpha Cognition, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
| Alpha Cognition | 0 | 0 | 5 | 0 | 3.00 |
Earnings & Valuation
This table compares IM Cannabis and Alpha Cognition”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IM Cannabis | $39.17 million | 0.02 | -$8.10 million | ($60.66) | -0.05 |
| Alpha Cognition | $10.22 million | 19.12 | -$20.67 million | ($1.10) | -8.15 |
IM Cannabis has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
7.7% of IM Cannabis shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
IM Cannabis has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500.
Summary
Alpha Cognition beats IM Cannabis on 9 of the 14 factors compared between the two stocks.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
